25 septiembre 2015

AMERICAN HEART ASSOCIATION. Sulodexide for the Prevention of Recurrent Venous Thromboembolism

Giuseppe M. Andreozzi, MD; Angelo A. Bignamini, PhD; Giovanni Davì, MD; Gualtiero Palareti, MD; Jiří Matuška, MD; Martin Holý, MD; Katarzyna Pawlaczyk-Gabriel, MD; Andrej Džupina, MD; German Y. Sokurenko, MD; Yury P. Didenko, MD; Laurentia D. Andrei, MD; Gianfranco Lessiani, MD; Adriana Visonà, MD

Background: Patients with a first episode of unprovoked venous thromboembolism have a high risk of recurrence after discontinuation of anticoagulant therapy. Extending anticoagulation reduces the risk of recurrence but is associated with increased bleeding. Sulodexide, a glycosaminoglycan, exerts antithrombotic and profibrinolytic actions with a low bleeding risk when administered orally, but its benefit for preventing recurrent venous thromboembolism is not well known.

14 octubre 2015

AMERICAN HEART ASSOCIATION. Red Blood Cell Dysfunction Induced by High-Fat Diet

Dusten Unruh, BS; Ramprasad Srinivasan, PhD; Tyler Benson, BA; Stephen Haigh, BA; Danielle Coyle, MS; Neil Batra, BA; Ryan Keil, BS; Robert Sturm, BS; Victor Blanco, PhD; Mary Palascak, BA; Robert S. Franco, PhD; Wilson Tong, MD; Tapan Chatterjee, PhD; David Y. Hui, PhD; W. Sean Davidson, PhD; Bruce J. Aronow, PhD; Theodosia Kalfa, MD, PhD; David Manka, PhD; Abigail Peairs, PhD; Andra Blomkalns, MD; David J. Fulton, PhD; Julia E. Brittain, PhD; Neal L. Weintraub, MD; Vladimir Y. Bogdanov, PhD

Background: High-fat diet (HFD) promotes endothelial dysfunction and proinflammatory monocyte activation, which contribute to atherosclerosis in obesity. We investigated whether HFD also induces the dysfunction of red blood cells (RBCs), which serve as a reservoir for chemokines via binding to Duffy antigen receptor for chemokines (DARC).

11 septiembre 2015

AMERICAN HEART ASSOCIATION. The Contemporary Safety and Effectiveness of Lower Extremity Bypass Surgery and Peripheral Endovascular Interventions in the Treatment of Symptomatic Peripheral Arterial Disease

Thomas T. Tsai, MD, MSc; Thomas F. Rehring, MD; R. Kevin Rogers, MD, MS; Susan M. Shetterly, MS; Nicole M. Wagner, MS; Rajan Gupta, MD; Omid Jazaeri, MD; Nasim Hedayati, MD; W. Schuyler Jones, MD; Manesh R. Patel, MD; P. Michael Ho, MD, PhD; Alan S. Go, MD; David J. Magid, MD, MPH

Background: Treatment for symptomatic peripheral artery disease includes lower extremity bypass surgery (LEB) and peripheral endovascular interventions (PVIs); however, limited comparative effectiveness data exist between the 2 therapies. We assessed the safety and effectiveness of LEB and PVI in patients with symptomatic claudication and critical limb ischemia.

05 noviembre 2014

AMERICAN HEART ASSOCIATION. Endovascular Treatment of Mycotic Aortic Aneurysms

Karl Sörelius, MD; Kevin Mani, MD, PhD; Martin Björck, MD, PhD; Petr Sedivy, MD, PhD; Carl-Magnus Wahlgren, MD, PhD; Peter Taylor, MA, MChir, FRCS; Rachel E. Clough, PhD, MRCS; Oliver Lyons, MRCS, PhD; Matt Thompson, MD, FRCS; Jack Brownrigg, MBChB, MRCS; Krassi Ivancev, MD, PhD; Meryl Davis, BSc, MBBS, FRCS; Michael P. Jenkins, BSc, MBBS, MS, FRCS, FEBVS; Usman Jaffer, BSc, MBBS, FRCS, MSc, PhD, PGCE, FHEA; Matt Bown, MD, FRCS; Zoran Rancic, MD, PhD; Dieter Mayer, MD; Jan Brunkwall, MD, PhD; Michael Gawenda, MD, PhD

Background: Mycotic aortic aneurysm (MAA) is a rare and life-threatening disease. The aim of this European multicenter collaboration was to study the durability of endovascular aortic repair (EVAR) of MAA, by assessing late infection–related complications and long-term survival.

13 noviembre 2014

AMERICAN HEART ASSOCIATION. Mortality From Thoracic Aortic Diseases and Associations With Cardiovascular Risk Factors

David Sidloff, MRCS, MBBS, BSc (Hon); Edward Choke, PhD, FRCS, MBBS; Philip Stather, MRCS, MBChB, MRCS; Matthew Bown, MD, FRCS, PGCert (Bioinformatics); John Thompson, PhD; Robert Sayers, MBChB (Hons), FRCS (Ed), FRCS (Eng), MD

Background: Temporal trends in mortality from thoracic aortic disease are unclear. This study examined trends in mortality from thoracic aortic aneurysm (TAA) and aortic dissection (AD) with the aim of identifying associations with trends in established cardiovascular risk factors.

03 diciembre 2014

AMERICAN HEART ASSOCIATION. Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease

Gunnar Tepe, MD; John Laird, MD; Peter Schneider, MD; Marianne Brodmann, MD; Prakash Krishnan, MD; Antonio Micari, MD; Christopher Metzger, MD; Dierk Scheinert, MD; Thomas Zeller, MD; David J. Cohen, MD, MSc; David B. Snead, PhD; Beaux Alexander, MBA; Mario Landini, MS; Michael R. Jaff, DO

Background: Drug-coated balloons (DCBs) have shown promise in improving the outcomes for patients with peripheral artery disease. We compared a paclitaxel-coated balloon with percutaneous transluminal angioplasty (PTA) for the treatment of symptomatic superficial femoral and popliteal artery disease.

19 septiembre 2014

AMERICAN HEART ASSOCIATION. Why Patients Know More About Cars Than Peripheral Artery Disease

Michael R. Jaff, DO, FACC

Americans who are interested in purchasing a motor vehicle often investigate automobile manufacturers, car models, and even competitive pricing using the World Wide Web. When one uses an Internet search engine to investigate Toyota, the largest automobile manufacturer in the world, there are >93 000 000 results. Virtually every possible question one would have about a Toyota vehicle is discoverable before ever visiting a local Toyota dealership.

19 septiembre 2014

AMERICAN HEART ASSOCIATION. Clinical Trials in Peripheral Vascular Disease

Sumeet Subherwal, MD, MBA; Manesh R. Patel, MD; Karen Chiswell, PhD; Beth A. Tidemann-Miller, PhD; W. Schuyler Jones, MD; Michael S. Conte, MD; Christopher J. White, MD; Deepak L. Bhatt, MD, MPH; John R. Laird, MD; William R. Hiatt, MD; Asba Tasneem, PhD; Robert M. Califf, MD

Background: Tremendous advances have occurred in therapies for peripheral vascular disease (PVD); until recently, however, it has not been possible to examine the entire clinical trial portfolio of studies for the treatment of PVD (both arterial and venous disease).

01 agosto 2015

AMERICAN HEART ASSOCIATION. Comparative Outcomes of Catheter-Directed Thrombolysis Plus Anticoagulation Versus Anticoagulation Alone in the Treatment of Inferior Vena Caval Thrombosis

Mohamad Alkhouli, MD, Chad J. Zack, MD, Huaqing Zhao, PhD, Irfan Shafi, MD and Riyaz Bashir, MD

Background: The contemporary practice patterns and role of catheter-directed thrombolysis (CDT) in the treatment of inferior vena cava thrombosis is unknown.

01 agosto 2015

AMERICAN HEART ASSOCIATION. Ultrasound-Assisted Versus Conventional Catheter-Directed Thrombolysis for Acute Iliofemoral Deep Vein Thrombosis

Rolf P. Engelberger, MD, David Spirk, MD, Torsten Willenberg, MD, Adriano Alatri, MD, Dai-Do Do, MD, Iris Baumgartner, MD and Nils Kucher, MD

Background: For patients with acute iliofemoral deep vein thrombosis, it remains unclear whether the addition of intravascular high-frequency, low-power ultrasound energy facilitates the resolution of thrombosis during catheter-directed thrombolysis.

01 abril 2016

AMERICAN HEART ASSOCIATION. Percutaneous Transluminal Angioplasty and Drug-Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia (PADI) Trial

Marlon I. Spreen, MD, Jasper M. Martens, MD, Bettina E. Hansen, PhD, Bob Knippenberg, MD, PhD, Elke Verhey, Lukas C. van Dijk, MD, PhD, Jean-Paul P.M. de Vries, MD, PhD, Jan-Albert Vos, MD, PhD, Gert Jan de Borst, MD, PhD, Evert-Jan P.A. Vonken, MD, PhD, Jan J. Wever, MD, PhD, Randolph G. Statius van Eps, MD, PhD, Willem P.Th.M. Mali, MD, PhD and Hans van Overhagen, MD, PhD

Background: Endovascular infrapopliteal treatment of patients with critical limb ischemia using percutaneous transluminal angioplasty (PTA) and bail-out bare metal stenting (BMS) is hampered by restenosis. In interventional cardiology, drug-eluting stents (DES) have shown better patency rates and are standard practice nowadays. An investigator-initiated, multicenter, randomized trial was conducted to assess whether DES also improve patency and clinical outcome of infrapopliteal lesions.

01 febrero 2016

AMERICAN COLLEGE OF CARDIOLOGY. Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan

Hiroyoshi Yokoi, MD; Takao Ohki, MD, PhD; Kimihiko Kichikawa, MD; Masato Nakamura, MD, PhD; Kimihiro Komori, MD, PhD; Shinsuke Nanto, MD, PhD; Erin E. O’Leary, PhD; Aaron E. Lottes, PhD; Scott A. Snyder, PhD; Michael D. Dake, MD

Background: The Zilver PTX stent is the first drug-eluting stent (DES) approved for the superficial femoral artery. Previously, results from a large randomized study and a complementary, large single-arm study supported the safety and effectiveness of the DES.

01 enero 2015

AMERICAN COLLEGE OF CARDIOLOGY. Randomized Controlled Study of Excimer Laser Atherectomy for Treatment of Femoropopliteal In-Stent Restenosis

Eric J. Dippel, MD; Prakash Makam, MD; Richard Kovach, MD; Jon C. George, MD; Raghotham Patlola, MD; D. Christopher Metzger, MD; Carlos Mena-Hurtado, MD; Robert Beasley, MD; Peter Soukas, MD; Pedro J. Colon-Hernandez, MD; Matthew A. Stark, PhD; Craig Walker, MD

Background: Femoropopliteal stenting has shown superiority to PTA for lifestyle-limiting claudication and critical limb ischemia, although treating post-stenting artery reobstruction, or ISR, remains challenging.

01 enero 2016

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. Time-course of vascular dysfunction of brachial artery after transradial access for coronary angiography

Jerson Munoz-Mendoza MD, Abhijit Ghatak MD, Veronica Pinto Miranda MD, Shaka Bahadu MD, Eduardo De Marchena MD, Alexandre C. Ferreira MD and Cesar E. Mendoza MD

Background: Prior studies have demonstrated endothelial and smooth muscle brachial artery dysfunction after transradial cardiac catheterization for diagnostic coronary angiography. The duration of this vascular dysfunction is unknown.

01 enero 2016

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. Outcomes of One straight-line flow with and without pedal arch in patients with critical limb ischemia

Akihiro Higashimori MD, Osamu Iida MD, Yasutaka Yamauchi MD, Daizo Kawasaki MD, Masato Nakamura MD, PhD, Yoshimitsu Soga MD, Kan Zen MD, Yoshiaki Yokoi MD, PhD, FSCAI, FJCC

Objectives: This study aimed to compare the outcomes of revascularization strategies for patients with critical limb ischemia (CLI) whereby single vessel run off to the foot was established with or without flow into a patent pedal arch.